 Hookipa Pharma Inc NASDAQ: HOOK amended and restated collaboration and license agreement with Gilead Sciences Inc NASDAQ: GILD for arenaviral immunotherapy as a component of a potential functional curative regimen for human immunodeficiency virus HIV. In April 2018, Gilead licensed exclusive rights to Hookipas arenaviral platform to develop immunotherapies for HIV and hepatitis B virus HBV. 